Unravelling the modes of action of microbiome therapies
Tim Sharpington, Chief Executive Officer at Microbiotica… Read More
Tim Sharpington, Chief Executive Officer at Microbiotica… Read More
Microbiotica has revealed new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC). The data were shared at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February in Banff, Canada and at the European… Read More